Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 16.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 10 |
On May 14, 2024, Blake Borgeson, Director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), executed a sale of 20,054 shares of the company.
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVID
Recursion Pharmaceuticals ( NASDAQ:RXRX ) First Quarter 2024 Results Key Financial Results Revenue: US$13.8m (up 14...